Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191923 | 0.91 | SLC6A2 (0.64) | SLC6A2SLC6A4MEN1KMT2AACP3 | |
| SCHEMBL3205738 | 0.88 | SLC6A2 (0.65) | SLC6A2SLC6A4ACP3 | |
| SCHEMBL3190940 | 0.86 | SLC6A2 (0.58) | SLC6A2SLC6A4 | |
| SCHEMBL3190947 | 0.86 | SLC6A2 (0.58) | SLC6A2SLC6A4 | |
| SCHEMBL3206018 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A4MEN1KMT2AACP3 | |
| SCHEMBL3201238 | 0.84 | SLC6A2 (0.66) | SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL3206053 | 0.84 | SLC6A2 (0.62) | SLC6A2SLC6A4 | |
| SCHEMBL3212618 | 0.84 | SLC6A2 (0.62) | SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL3197684 | 0.81 | SLC6A2 (0.55) | SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL29173911 | 0.81 | SLC6A2 (0.52) | SLC6A2SLC6A4MEN1KMT2AACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671238-B2 | Arylamino-arylpropanolamine derivatives and methods of their use | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2008042362-A1 | ARYLAMINO-ARYLPROPANOLAMINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080085938-A1 | Arylamino-Arylpropanolamine Derivatives and Methods of Their Use | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085938-A1 | Arylamino-Arylpropanolamine Derivatives and Methods of Their Use | PNMT, PAH, SLC18A2 | SLC6A2 4/4885SLC6A4 6/4885MEN1 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.